NOVOMEDLINK™
  1. Activella®

    (estradiol/norethindrone acetate tablets)

  2. Vagifem®

    (estradiol vaginal tablets)

  3. GlucaGen® HypoKit®

    (glucagon [rDNA Origin] for injection)

  4. Levemir®

    (insulin detemir [rDNA origin] injection)

  5. Norditropin®

    (somatropin (rDNA origin) injection)

  6. NovoLog®

    (Insulin aspart [rDNA origin] injection)

  7. NovoLog® Mix 70/30

    (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])

  8. NovoSeven® RT

    Coagulation Factor VIIa (Recombinant) Room
    Temperature Stable

  9. NovoSeven®

    (Coagulation Factor VIIa [Recombinant])

FlexPen®: patient-preferred14,17

The #1 selling prefilled insulin pen in the world2

  • More than 5 years on the market1
  • More than 1.7 million users18
  • An impressive amount of real-world experience

User-friendly design provides important benefits that fit many lifestyles

  • Proven accuracy
  • Easy to learn, easy to use, and easy to teach
  • Distinctly color-branded
  • Convenient options: Levemir®, NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection [rDNA origin]), and NovoLog® (insulin aspart [rDNA origin]) are each available in FlexPen®

Recommended for use with NovoFine® 30 needles

  • Practically pain-free: 90% of patients surveyed found NovoFine 30 needles practically pain-free19
  • Built for safe handling: NovoFine® Autocover® is designed to reduce the risk of needlestick injuries

† Depending on insulin used (NovoLog® Mix 70/30 = 14 days; NovoLog® = 28 days; Levemir® = 42 days).

‡ Needles are sold separately and may require a prescription in some states.

FlexPen® is patient-preferred over competitor's pen and vial/syringe14,17

§ Multicenter, randomized, open-label, crossover study of 121 patients with type 1 or 2 diabetes mellitus transferred from previous once-daily or BID conventional insulin therapy to NovoLog® Mix 70/30 assessing patient preference, efficacy, and safety. Intent-to-treat population: N=105.17

|| 6% of respondents had no preference.17

Multicenter, randomized, open-label, 2-way, crossover (two 12-week periods) trial in 137 insulin-experienced patients with type 2 diabetes mellitus comparing efficacy of, safety of, and device preference for NovoLog® Mix 70/30 FlexPen and lispro mix 75/25 pen. Satisfaction with pen devices was assessed using 2 device-specific questionnaires and a comparative questionnaire at end of study. Intent-to-treat population: N=132.14

# 17% of respondents had no preference.14

Follow the instructions below to see a demonstration of Levemir® FlexPen® and how it works

The QuickGuide is presented in Macromedia Flash. If you don't have the proper plug-in, you can download it free by clicking on the button below.

Get Macromedia Flash Player

  1. Levemir® (insulin detemir [rDNA origin] injection) Indications and Usage

    Levemir® is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

    Levemir® Important Safety Information

    Levemir® is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

    Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir®. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Levemir® is not to be used in insulin infusion pumps. Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

    Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Levemir® should not be diluted or mixed with any other insulin preparations. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir® from other intermediate or long-acting insulin preparations. The dose of Levemir® may need to be adjusted in patients with renal or hepatic impairment.

    Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation. Less common, but more serious are severe cases of generalized allergy, including anaphylactic reaction, which may be life threatening.

    Please see Prescribing Information.

Levemir®, NovoLog®, NovoLog® Mix 70/30, GlucaGen®, Novolin®, and Autocover® are registered trademarks of Novo Nordisk A/S. NovoSeven® RT and Norditropin® are registered trademarks of Novo Nordisk Health Care AG. Activella® 1.0 mg/0.5 mg, Activella® 0.5 mg/0.1 mg, and Vagifem® are registered trademarks of Novo Nordisk FemCare AG.